{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urgent+Surgery", "query": { "condition": "Urgent Surgery" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urgent+Surgery&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T16:09:18.604Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04233073", "title": "Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Surgery" ], "interventions": [ { "name": "andexanet alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "84 Years", "sex": "ALL", "summary": "18 Years to 84 Years" }, "enrollment_count": 10, "start_date": "2021-06-27", "completion_date": "2022-01-25", "has_results": true, "last_update_posted_date": "2023-03-22", "last_synced_at": "2026-07-22T16:09:18.604Z", "location_count": 20, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Moreno Valley", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04233073" }, { "nct_id": "NCT03952299", "title": "Oxybutynin for Post-surgical Bladder Pain and Urgency", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Overactive Bladder Syndrome", "Neuropathic Bladder" ], "interventions": [ { "name": "Oxybutynin Transdermal Patch", "type": "DRUG" }, { "name": "Oral Oxybutynin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "8 Years", "sex": "ALL", "summary": "4 Years to 8 Years" }, "enrollment_count": 100, "start_date": "2021-09-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-07-22T16:09:18.604Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03952299" }, { "nct_id": "NCT07288489", "title": "Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Blood Loss, Surgical", "Coagulation Disorder" ], "interventions": [ { "name": "VMX-C001", "type": "DRUG" }, { "name": "Usual Pharmacological Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VarmX B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 800, "start_date": "2026-03", "completion_date": "2031-01", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-07-22T16:09:18.604Z", "location_count": 16, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Stanford, California + 12 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Stanford", "state": "California" }, { "city": "Englewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07288489" }, { "nct_id": "NCT00803101", "title": "An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Reversal of Coagulopathy" ], "interventions": [ { "name": "Beriplex® P/N (Kcentra)", "type": "BIOLOGICAL" }, { "name": "Fresh frozen plasma", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "CSL Behring", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 176, "start_date": "2009-02", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2015-04-06", "last_synced_at": "2026-07-22T16:09:18.604Z", "location_count": 16, "location_summary": "Newark, Delaware • Lexington, Kentucky • Boston, Massachusetts + 13 more", "locations": [ { "city": "Newark", "state": "Delaware" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Duluth", "state": "Minnesota" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00803101" }, { "nct_id": "NCT05093504", "title": "Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hemorrhage, Surgical", "Hemorrhage Postoperative", "Blood Loss, Surgical", "Blood Loss, Postoperative" ], "interventions": [ { "name": "Sham comparator", "type": "DEVICE" }, { "name": "DrugSorb-ATR system", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "CytoSorbents, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2021-12-27", "completion_date": "2024-01-29", "has_results": true, "last_update_posted_date": "2025-05-04", "last_synced_at": "2026-07-22T16:09:18.604Z", "location_count": 27, "location_summary": "Sacramento, California • Denver, Colorado • New Haven, Connecticut + 22 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05093504" }, { "nct_id": "NCT04286438", "title": "Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hemorrhage", "Urgent Surgery", "Invasive Procedure" ], "interventions": [ { "name": "Bentracimab (PB2452) Infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SFJ Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2020-07-15", "completion_date": "2024-09-09", "has_results": false, "last_update_posted_date": "2024-10-21", "last_synced_at": "2026-07-22T16:09:18.604Z", "location_count": 9, "location_summary": "Jacksonville, Florida • Lexington, Kentucky • Baltimore, Maryland + 6 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "North Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04286438" }, { "nct_id": "NCT05156983", "title": "A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Coagulation Disorder" ], "interventions": [ { "name": "TAK-330", "type": "DRUG" }, { "name": "SOC 4F-PCC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 440, "start_date": "2022-08-24", "completion_date": "2028-08-30", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-07-22T16:09:18.604Z", "location_count": 13, "location_summary": "Arkansas City, Arkansas • Sacramento, California • Englewood, Colorado + 10 more", "locations": [ { "city": "Arkansas City", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05156983" }, { "nct_id": "NCT03043222", "title": "Innovative Minimally Invasive Options in Treatment of Urinary Problems Related to Prostate Enlargement (BPH) in Men", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lower Urinary Tract Symptoms", "Benign Prostatic Hyperplasia", "Urinary Frequency/Urgency", "Urinary Incontinence, Urge", "Incontinence, Urinary", "Nocturia" ], "interventions": [ { "name": "UroLift as artifical device for prostatic urethral lift.", "type": "DEVICE" }, { "name": "Embospheres Microspheres as embolic agents for prostate artery embolization", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "St. Louis University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "MALE", "summary": "40 Years and older · Male only" }, "enrollment_count": 0, "start_date": "2018-03-01", "completion_date": "2019-06-01", "has_results": false, "last_update_posted_date": "2018-03-20", "last_synced_at": "2026-07-22T16:09:18.604Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03043222" }, { "nct_id": "NCT02740335", "title": "Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Significant Bleeding Risk" ], "interventions": [ { "name": "Octaplex", "type": "DRUG" }, { "name": "Beriplex P/N (Kcentra)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Octapharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 208, "start_date": "2017-06-08", "completion_date": "2022-02-23", "has_results": true, "last_update_posted_date": "2023-03-08", "last_synced_at": "2026-07-22T16:09:18.604Z", "location_count": 22, "location_summary": "Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 14 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT02740335" }, { "nct_id": "NCT04807920", "title": "BOTOX® at the Time of Prolapse Surgery for OAB", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Urinary Bladder, Overactive", "Pelvic Organ Prolapse" ], "interventions": [ { "name": "OnabotulinumtoxinA 100 UNT", "type": "DRUG" }, { "name": "Injectable saline", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Walter Reed National Military Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 138, "start_date": "2021-09-23", "completion_date": "2023-06", "has_results": false, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-07-22T16:09:18.604Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04807920" } ] }